Testosterone cypionate dominates the TRT landscape for a simple reason: it works predictably across a wide patient population with minimal administration burden. The long half-life of approximately 8 days allows weekly or twice-weekly injections that maintain stable blood levels without the frequent dosing required by shorter esters like propionate.

Most TRT clinics in 2026 start patients at 100–150mg testosterone cypionate per week, split into two doses of 50–75mg administered every 3.5 days. This frequency minimizes the peak-to-trough swings that cause mood changes and aromatization spikes. Some patients respond well to single weekly doses of 100–200mg, but symptom resolution is typically better with divided doses.

The standard 200mg/mL concentration means you’re injecting 0.5mL to 0.75mL per dose—manageable volumes for both intramuscular and subcutaneous administration. Subcutaneous administration at these volumes creates less scar tissue buildup than intramuscular, and a 2017 study published in Urology (Fernandez-Balsells et al.) found no difference in efficacy between routes when total weekly dose remained constant.

Why Cypionate Over Other Esters

Testosterone cypionate and enanthate share nearly identical pharmacokinetics—both are long-acting esters with half-lives around 7–8 days. The choice between them often comes down to availability. In the United States, cypionate is manufactured domestically and more widely stocked. Enanthate is more common internationally but functionally interchangeable at equivalent doses.

Propionate requires injection every other day or daily due to its 2–3 day half-life. This frequency improves nothing for most patients while dramatically increasing injection burden and site rotation challenges. Undecanoate (Nebido, Aveed) extends dosing intervals to 10–12 weeks but creates massive peaks and troughs that many patients find intolerable.

The 2019 guidelines from the American Urological Association reference testosterone cypionate and enanthate as first-line agents specifically because decades of clinical data support predictable dosing, reliable absorption, and straightforward titration based on patient response.

Standard Dosing Ranges and Titration

FDA labeling lists 50–400mg every 2–4 weeks as the approved range. This creates confusion because modern protocols reject that dosing interval as outdated. A 400mg dose every two weeks creates a supraphysiologic spike followed by a crash below baseline—exactly the pattern that causes patients to complain about “feeling great for five days, then terrible.”

Clinical practice in 2026 uses weekly or twice-weekly dosing exclusively for cypionate. The effective range looks like this:

75–100mg per week: Conservative starting dose for older patients, those concerned about fertility preservation, or individuals with elevated hematocrit risk
100–150mg per week: Most common starting dose, split into 50–75mg twice weekly
150–200mg per week: Higher therapeutic range for larger patients or those who require more aggressive symptom management
200mg+ per week: Reserved for non-responders or patients with unusually high SHBG binding that reduces free testosterone availability

Total testosterone levels on these protocols typically land between 600–1200 ng/dL at trough (measured just before next injection). Free testosterone ranges between 15–30 pg/mL depending on SHBG levels and total dose.

The 264 ng/dL Lower Limit Problem

The standard laboratory reference range for total testosterone bottoms out around 264–300 ng/dL depending on the lab. This number comes from the NHANES III population study conducted in the 1980s and 1990s that included elderly men, many with chronic illness, obesity, and metabolic dysfunction. Using that cohort to define “normal” for a 35-year-old male with symptoms is medical gatekeeping disguised as evidence-based medicine.

A healthy 25-year-old male typically has total testosterone between 600–900 ng/dL. Telling a symptomatic patient with levels at 350 ng/dL that he’s “technically normal” ignores both symptom burden and the fact that his testosterone is half what it should be for his age. The 2017 study by Travison et al. in the Journal of Clinical Endocrinology & Metabolism demonstrated that testosterone levels have declined across successive generations even when controlling for obesity and chronic disease—meaning today’s reference ranges reflect population-level decline, not optimal health.

Injection Technique and Site Rotation

Intramuscular administration traditionally targets the gluteus or vastus lateralis muscles with 1–1.5 inch needles. Subcutaneous injection uses shorter insulin syringes (typically 27–30 gauge, 0.5 inch) and can be performed in abdominal or thigh adipose tissue.

Subcutaneous protocols reduce injection discomfort and make daily or every-other-day microdosing practical. A 2014 study in The Journal of Clinical Endocrinology & Metabolism (Spratt et al.) showed that daily subcutaneous testosterone maintained more stable levels than weekly intramuscular dosing, though the clinical significance of ultra-stable levels versus standard twice-weekly protocols remains debated.

Site rotation prevents lipohypertrophy and scar tissue formation. Eight rotation sites (four abdominal quadrants, bilateral anterior thighs, bilateral deltoids, bilateral glutes) allow sufficient healing time between injections at the same location.

Managing Estradiol on Cypionate

Testosterone aromatizes to estradiol at rates that vary significantly between individuals based on body composition, aromatase enzyme activity, and genetics. Most men on 100–150mg weekly cypionate maintain estradiol levels between 20–40 pg/mL without intervention. This range supports libido, bone density, and mood stability.

Some patients aromatize heavily and develop estradiol levels above 50–60 pg/mL, which can cause water retention, sensitive nipples, and mood changes. Small doses of anastrozole—0.25–0.5mg twice weekly—typically bring estradiol into target range. The goal is not to crash estradiol to single digits (which destroys libido and joint health) but to maintain it proportional to testosterone levels.

Starting anastrozole preemptively is a mistake. Run bloodwork 6 weeks into TRT, assess symptoms and estradiol levels, then intervene only if needed. Some patients feel best with estradiol at 45 pg/mL. Others need it at 25 pg/mL. Individual response beats arbitrary targets.

HCG as Adjunct Therapy

Human chorionic gonadotropin preserves testicular function and fertility during TRT by mimicking luteinizing hormone. Standard dosing runs 250–500 IU subcutaneously 2–3 times per week alongside testosterone injections.

HCG prevents testicular atrophy, maintains intratesticular testosterone production, and supports downstream hormone pathways including pregnenolone and DHEA. The trade-off is increased estradiol production because HCG stimulates testicular aromatase. Patients using HCG often require slightly lower testosterone doses or small amounts of anastrozole to manage estradiol.

Men unconcerned with fertility often skip HCG to simplify their protocol and reduce aromatization. Those planning future fertility should run HCG continuously rather than attempting to restart testicular function after years of suppression.

Lab Monitoring Protocol

Baseline labs before starting cypionate should include total testosterone, free testosterone, estradiol (sensitive assay), complete blood count, comprehensive metabolic panel, lipid panel, PSA (for men over 40), and thyroid panel.

Follow-up labs at 6 weeks assess initial response and guide dose titration. Steady-state labs every 12 weeks for the first year, then every 6 months once dialed in. Timing matters—draw blood at trough (just before next injection) for twice-weekly protocols to assess your lowest levels.

Target ranges on TRT:

Total testosterone: 600–1200 ng/dL at trough
Free testosterone: 15–30 pg/mL
Estradiol: 20–40 pg/mL (individual variation applies)
Hematocrit: Below 52–54%
Hemoglobin: Below 17–18 g/dL

Hematocrit elevation is the most common side effect requiring intervention. Therapeutic phlebotomy every 8–12 weeks manages this when levels creep above 52%. Some patients switch to more frequent, lower doses (daily microdosing at 15–20mg) to reduce hematocrit response.

Enclomiphene as Alternative First-Line

Before committing to exogenous testosterone, some clinics trial enclomiphene citrate at 12.5–25mg daily or every other day. This selective estrogen receptor modulator blocks negative feedback at the pituitary, increasing LH and FSH output, which stimulates natural testosterone production.

Enclomiphene works best for younger patients with secondary hypogonadism (low LH and testosterone) rather than primary testicular failure. Response rates vary—some men achieve 400–600 ng/dL increases, others see minimal change. Benefits include preserved fertility and natural hormone pathway maintenance. Drawbacks include less predictable dosing and symptom resolution compared to exogenous testosterone.

A 2015 study in BJU International (Wiehle et al.) showed enclomiphene increased testosterone from baseline 272 ng/dL to 612 ng/dL after 3 months at 25mg daily while maintaining normal LH and FSH. Not every patient responds this well, but it’s worth trialing before accepting lifelong injections.

Cypionate Stability and Storage

Testosterone cypionate remains stable at room temperature for months but degrades faster with heat and light exposure. Store vials at 68–77°F in original packaging. Refrigeration extends shelf life but isn’t necessary for standard 10mL vials used within 6 months.

Multi-dose vials contain benzyl alcohol as preservative, allowing sterile withdrawals over time. Use proper technique: alcohol swab the stopper, fresh needle each draw, never reuse needles between vial access and injection. Contamination risk with home administration is low but increases with sloppy technique.

Why Cypionate Became the Standard

Prescribing patterns favor cypionate in the United States because it’s domestically manufactured by multiple pharmaceutical companies and generic suppliers. This competition keeps pricing reasonable compared to branded alternatives like Aveed (testosterone undecanoate) that can run $1000+ per dose.

The predictable 8-day half-life makes dose adjustments straightforward. Patient reports feeling low? Increase weekly dose by 10–20mg and recheck labs in 6 weeks. Hematocrit climbing? Drop dose by 25mg weekly or split into more frequent smaller injections.

Testosterone pellets (Testopel) eliminate injection frequency but require surgical implantation every 3–4 months, offer no dose flexibility between implants, and carry infection risk at insertion sites. Transdermal gels work for some patients but create transfer risk to partners and children, plus absorption varies dramatically between individuals.

Injectable cypionate gives patients control over their protocol, allows precise dose titration, and costs $30–80 monthly through most compounding pharmacies. The combination of efficacy, safety data, and practical administration explains why it remains the gold standard two decades after TRT became mainstream medical practice.

Testosterone Cypionate: The Gold Standard TRT Protocol